Third, the effects of PD-1 immune checkpoint therapy have been shown to differ between the sexes (29) and are associated with serious immune-related cardiovascular adverse events, including autoimmune myocarditis, pericarditis, and vasculitis (11, 27, 28). Here, PDCD1 is linked to vasculitis.